Clinical Trials

6,720 enrolled

Burkitt Lymphoma, Down Syndrome, Precursor B-Cell Lymphoblastic Leukemia-Lymphoma

NCT04633252 2026-05-27

A Phase I/II Study of PDS01ADC With Docetaxel and Abiraterone in Adults With Metastatic Castration Sensitive and PDS01ADC With Docetaxel in Castration Resistant Prostate Cancer

Phase 1/2 Recruiting

86 enrolled

Genitourinary

Prostatic Neoplasms

NCT05675410 2026-05-27

A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab

Phase 3 Recruiting

1,875 enrolled

Lugano Classification Limited Stage Hodgkin Lymphoma AJCC v8

NCT06124157 2026-05-27

A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)

Phase 2 Recruiting

222 enrolled

Burkitt Lymphoma

NCT00092222 2026-05-22

Virotherapy and Natural History Study of KHSV-Associated Multricentric Castleman s Disease With Correlates of Disease Activity

75 enrolled

Multi-centric Castleman's Disease, Macular dystrophy, corneal type 1, Lymphadenopathy, Lymphoproliferative Disorders, Neoplasms, HIV Infections

NCT03223610 2026-05-22

Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed/Refractory B-cell Lymphoma

Phase 1/2 Recruiting

155 enrolled

Burkitt Lymphoma, Lymphoma, Lymphoma, Non-Hodgkin, Lymphoma, Large B-Cell, Diffuse

NCT03860987 2026-05-22

Neoadjuvant Androgen Deprivation Therapy Combined With Enzalutamide and Abiraterone Using Multiparametric MRI and 18FDCFPyL PET/CT in Newly Diagnosed Prostate Cancer

12 enrolled

Genitourinary

Castrate Sensitive Prostate Cancer

NCT06317662 2026-05-22

Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia

Phase 2 Recruiting

153 enrolled

Burkitt Lymphoma, Leukemia, Biphenotypic, Acute

NCT03269669 2026-05-13

Obinutuzumab With or Without Umbralisib, Lenalidomide, or Combination Chemotherapy in Treating Patients With Relapsed or Refractory Grade I-IIIa Follicular Lymphoma

73 enrolled

Phase 2/3 Active not recruiting

Lymphoma, Follicular

NCT03984448 2026-05-13

Testing the Addition of a New Anti-cancer Drug, Venetoclax, to Usual Chemotherapy for High Grade B-cell Lymphomas

363 enrolled

Lymphoma, Large B-Cell, Diffuse

NCT04301076 2026-05-13

Testing the Addition of an Anti-cancer Drug, Lenalidomide, to the Usual Combination Chemotherapy Treatment ("EPOCH") for Adult T-Cell Leukemia-Lymphoma (ATLL)

Phase 1 Suspended

30 enrolled

Phase 2/3 Active not recruiting

Lymphoma, HTLV-I Infections, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

NCT04799275 2026-05-13

Testing CC-486 (Oral Azacitidine) Plus the Standard Drug Therapy in Patients 75 Years or Older With Newly Diagnosed Diffuse Large B Cell Lymphoma

422 enrolled

Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone

NCT05896839 2026-05-13

Immunotherapy in Combination With Prednisone and Sirolimus for Kidney Transplant Recipients With Unresectable or Metastatic Skin Cancer

Phase 1/2 Recruiting

16 enrolled

Dermatologic

Carcinoma, Basal Cell, Melanoma, Carcinoma, Merkel Cell

NCT06649812 2026-05-13

Testing the Effectiveness of a Combination Targeted Therapy (ViPOR) for Patients With Relapsed and/or Refractory Aggressive B-cell Lymphoma

Phase 2 Recruiting

120 enrolled

Phase 1 Not yet recruiting

Lymphoma, Large B-Cell, Diffuse

NCT07444710 2026-05-13

Testing the Addition of an Anti-Cancer Drug, Glofitamab, to the Usual Chemotherapy Treatment (Alternating R-CHOP/R-DHAP) for Previously Untreated Mantle Cell Lymphoma

16 enrolled

Ann Arbor Stage II Mantle Cell Lymphoma

NCT02883049 2026-05-04

Combination Chemotherapy in Treating Young Patients With Newly Diagnosed High-Risk B Acute Lymphoblastic Leukemia and Ph-Like TKI Sensitive Mutations

5,949 enrolled 28 charts

Burkitt Lymphoma

NCT02003222 2026-05-01

Combination Chemotherapy With or Without Blinatumomab in Treating Patients With Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia

488 enrolled 13 charts 1 FDA

Phase 1 Active not recruiting

Burkitt Lymphoma, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT03816332 2026-04-30

Tacrolimus, Nivolumab, and Ipilimumab in Treating Kidney Transplant Recipients With Selected Unresectable or Metastatic Cancers

12 enrolled 13 charts

Dermatologic

Carcinoma, Basal Cell, Melanoma, Carcinoma, Merkel Cell

NCT00602641 2026-04-29

Melphalan, Prednisone, and Thalidomide or Lenalidomide in Treating Patients With Newly Diagnosed Multiple Myeloma

306 enrolled 12 charts

Plasma cell

Multiple Myeloma

NCT04739813 2026-04-29

Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid in Combination With Polatuzumab (ViPOR-P) in Relapsed/Refractory B-cell Lymphoma

Phase 1 Recruiting

55 enrolled

Burkitt Lymphoma, Lymphoma, Lymphoma, Non-Hodgkin, Lymphoma, Large B-Cell, Diffuse

NCT05389423 2026-04-28

Pomalidomide and Dose-Adjusted EPOCH +/- Rituximab for HIV-Associated Lymphomas

Phase 1 Recruiting

25 enrolled

Plasmablastic Lymphoma, Burkitt Lymphoma, Lymphoma, Non-Hodgkin, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Epstein-Barr Virus Infections

NCT00792948 2026-04-13

Combination Chemotherapy With or Without Donor Stem Cell Transplant in Treating Patients With Acute Lymphoblastic Leukemia

97 enrolled 7 charts

Burkitt Lymphoma, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

NCT02143414 2026-04-13

Blinatumomab and Combination Chemotherapy or Dasatinib, Prednisone, and Blinatumomab in Treating Older Patients With Acute Lymphoblastic Leukemia

53 enrolled 12 charts

Phase 1 Active not recruiting

Burkitt Lymphoma, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT03220022 2026-04-13

Ibrutinib, Rituximab, Etoposide, Prednisone, Vincristine Sulfate, Cyclophosphamide, and Doxorubicin Hydrochloride in Treating Patients With HIV-Positive Stage II-IV Diffuse Large B-Cell Lymphomas

46 enrolled 19 charts

Lymphoma, AIDS-Related

NCT05371054 2026-02-23

Study of VIP152, Venetoclax, and Prednisone (VVIP) in Relapsed/Refractory Lymphoid Malignancies

Phase 1/2 Completed

8 enrolled 20 charts

Lymphoma, Lymphoma, Non-Hodgkin, Hematologic Neoplasms

NCT04294641 2026-01-23

Front Line Ibrutinib Without Corticosteroids for Newly Diagnosed Chronic Graft-versus-Host Disease

Other hematologic neoplasm

10 enrolled 15 charts

Bronchiolitis Obliterans Syndrome, Hematologic Neoplasms

NCT00006436 2025-12-30

EPOCH and Rituximab to Treat Non-Hodgkin's Lymphoma in Patients With HIV Infection

68 enrolled 24 charts

LymphoidMyeloidOther hematologic neoplasmPlasma cell

Acquired Immunodeficiency Syndrome, Neoplasms, Lymphoma, Large B-Cell, Diffuse, Lymphoma, AIDS-Related

NCT02356159 2025-09-30

Study of Palifermin (Kepivance) in Persons Undergoing Unrelated Donor Allogeneic Hematopoietic Cell Transplantation

Phase 1/2 Completed

34 enrolled 18 charts

Hodgkin Disease, Leukemia, Lymphoma, Lymphoma, Non-Hodgkin, Multiple Myeloma, Myelodysplastic Syndromes

NCT02911142 2025-07-28

Lenalidomide Combined With Modified DA-EPOCH and Rituximab (EPOCH-R2) in Primary Effusion Lymphoma or KSHV-associated Large Cell Lymphoma

Phase 1/2 Active not recruiting

17 enrolled 21 charts

Lymphoma, B-Cell, Lymphoma, AIDS-Related, Lymphoma, Primary Effusion

NCT00001337 2025-06-22

Dose-Adjusted EPOCH Chemotherapy and Rituximab (CD20+) in Previously Untreated Aggressive Non-Hodgkin's Lymphoma

348 enrolled 15 charts

Burkitt Lymphoma, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Large-Cell, Anaplastic

NCT00001379 2025-06-19

Treatment and Natural History Study of Lymphomatoid Granulomatosis

94 enrolled 20 charts